SPT inhibition, either genetically or pharmacologically, has been shown to alleviate the neurological phenotypes in disease models for FRDA, INAD, and PINK1-PD, suggesting a strategy for treatment (Chen et al., 2016b; Lin et al., 2018; Vos et al., 2021). This evidence concerns the gene AGXT and Parkinson disease.